Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus XELOX for unresectable colorectal cancer with liver-only metastases
ChiCTR2300079171Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoints: Drug safety, Recommended phase II dose and 2 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
fruquintinibcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300079171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079171.